© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Acorda Therapeutics, Inc. (ACOR) stock declined over -24.02%, trading at $0.66 on NASDAQ, down from the previous close of $0.87. The stock opened at $0.78, fluctuating between $0.61 and $0.85 in the recent session.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Employees | 102 |
Beta | 1.46 |
Sales or Revenue | $117.63M |
5Y Sales Change% | -0.921% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Acorda Therapeutics, Inc. (NASDAQ: ACOR) stock price is $0.66 in the last trading session. During the trading session, ACOR stock reached the peak price of $0.85 while $0.61 was the lowest point it dropped to. The percentage change in ACOR stock occurred in the recent session was -24.02% while the dollar amount for the price change in ACOR stock was -$0.21.
The NASDAQ listed ACOR is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Acorda Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Kerry M. Clem
Chief Commercial Officer
Mr. Andrew Mayer J.D.
Senior Vice President
Ms. Tierney Saccavino
Executive Vice President of Corporation Communications
Dr. Burkhard Blank M.D.
Interim Head of Drug Safety
Sofia Ali
Senior Vice President of Operations & Strategic Planning
Ms. Felicia Vonella
Vice President of Investor Relations
Ms. Denise J. Duca
Executive Vice President of HR
Mr. Michael A. Gesser M.B.A.
Chief Financial Officer
Mr. Neil S. Belloff Esq.
Gen. Counsel & Corporation Sec.
Dr. Ron Cohen M.D.
Founder, Chief Executive Officer, Pres & Director
Mr. Robert Morales
Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Fin. & Controller
ACOR's closing price is 8.08% higher than its 52-week low of $0.61 where as its distance from 52-week high of $24.20 is -97.27%.
Number of ACOR employees currently stands at 102.
Official Website of ACOR is: https://www.acorda.com
ACOR could be contacted at phone 914 347 4300 and can also be accessed through its website. ACOR operates from 420 Saw Mill River Road, Ardsley, NY 10502, United States.
ACOR stock volume for the day was 321.67K shares. The average number of ACOR shares traded daily for last 3 months was 125.68K.
The market value of ACOR currently stands at $821.03K with its latest stock price at $0.66 and 1.24M of its shares outstanding.